openPR Logo
Press release

Overt Hepatic Encephalopathy (OHE) Market New Product Development & Latest Trends

08-26-2025 01:19 PM CET | Health & Medicine

Press release from: Exactitude Consultancy

Overt Hepatic Encephalopathy (OHE) Market

Overt Hepatic Encephalopathy (OHE) Market

Introduction
Overt Hepatic Encephalopathy (OHE) is a serious and potentially life-threatening complication of chronic liver disease, particularly cirrhosis. It results from the accumulation of neurotoxins, especially ammonia, in the bloodstream, impairing brain function. Patients present with altered mental status, confusion, motor dysfunction, and in severe cases, coma. OHE not only worsens quality of life but also increases hospitalization rates and mortality risk, representing a major healthcare challenge worldwide.

As liver diseases such as cirrhosis, alcoholic liver disease, viral hepatitis, and nonalcoholic steatohepatitis (NASH) continue to rise, the prevalence of OHE is also increasing. With growing awareness, enhanced diagnostic capabilities, and expansion of therapeutic options such as lactulose, rifaximin, and emerging biologics, the OHE market is set for sustained growth in the next decade.

Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71156

Market Overview
• Market Size (2024): Approximately USD 1.4 billion
• Forecast (2034): Approximately USD 2.9 billion
• CAGR (2025-2034): 7.5%

Key Growth Drivers:
• Rising prevalence of chronic liver diseases, cirrhosis, and NASH.
• Increasing hospital admissions for OHE-related complications.
• Expanding use of rifaximin and lactulose as standard therapies.
• Growing research interest in microbiome-based and biologic therapies.
• Healthcare investment in emerging economies.

Key Restraints:
• High cost of rifaximin and advanced therapies.
• Lack of curative treatment; current therapies focus only on symptom control.
• Low awareness and late diagnosis in low-income regions.

Segmentation Analysis
The OHE market can be segmented as follows:
• By Drug Class:
o Lactulose (first-line therapy)
o Rifaximin (commonly prescribed as adjunct)
o L-ornithine L-aspartate (LOLA)
o Probiotics and microbiome-based therapies
o Pipeline biologics and novel ammonia-lowering agents

• By Route of Administration:
o Oral therapies (dominant)
o Injectable formulations

• By End Use:
o Hospitals (acute care and in-patient management)
o Specialty liver clinics (chronic management)
o Retail and hospital pharmacies
o Home care settings

• By Patient Type:
o Cirrhosis-related OHE
o Alcoholic liver disease-related OHE
o NASH-related OHE
o Other liver-related causes

Summary: Lactulose remains the most widely prescribed drug due to affordability and effectiveness. Rifaximin has gained traction for reducing recurrence, particularly in developed markets. Hospitals dominate in end-use as acute management requires in-patient treatment, but specialty clinics are increasingly critical for long-term care.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/71156/overt-hepatic-encephalopathy-market

Regional Analysis
• North America:
The leading market due to high prevalence of cirrhosis, strong adoption of rifaximin, and robust reimbursement systems. The U.S. dominates, with large-scale clinical trials and active research in advanced therapies.
• Europe:
A major market supported by well-established healthcare infrastructure and high awareness of liver disease. Germany, France, the UK, and Italy are key contributors.
• Asia-Pacific:
Expected to record the fastest CAGR, driven by large patient populations in China and India, high prevalence of hepatitis and NASH, and growing investment in healthcare. Japan and South Korea lead in adopting advanced liver disease management solutions.
• Middle East & Africa:
Gradual growth, supported by high rates of viral hepatitis and alcoholic liver disease. Limited access to advanced therapies remains a challenge.
• Latin America:
Brazil, Mexico, and Argentina are emerging as key markets, with growing adoption of lactulose and rifaximin supported by healthcare reforms.

Regional Summary: North America and Europe dominate revenues today, but Asia-Pacific is expected to emerge as the fastest-growing region by 2034 due to its high disease burden and rapidly improving healthcare systems.

Market Dynamics
Key Growth Drivers:
• Growing prevalence of advanced liver disease globally.
• Strong adoption of rifaximin-lactulose combination therapy.
• Regulatory incentives for orphan and rare disease treatments.
• Rising healthcare spending in developing economies.

Key Challenges:
• High treatment costs restrict access in low- and middle-income countries.
• Lack of therapies addressing the root cause of OHE.
• Difficulties in patient adherence, particularly with lactulose.

Latest Trends:
• Development of microbiome-based therapies to reduce ammonia-producing gut bacteria.
• Increased investment in biologics and targeted agents for ammonia metabolism.
• Growth of telemedicine and remote patient monitoring for long-term management.
• Use of digital biomarkers and AI for cognitive assessment in OHE patients.

Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71156

Competitor Analysis
Key Players:
• Bausch Health Companies (Salix - rifaximin)
• Abbott Laboratories (lactulose formulations)
• Fresenius Kabi
• Mallinckrodt Pharmaceuticals
• Cosmo Pharmaceuticals
• Takeda Pharmaceutical Company
• Gilead Sciences
• Novartis AG
• Lupin Pharmaceuticals
• Johnson & Johnson

Competitive Landscape:
The OHE market is moderately consolidated. Bausch Health dominates with rifaximin, while Abbott and Fresenius are leaders in lactulose therapies. Emerging biotech firms are focusing on novel ammonia-lowering agents and microbiome therapies. Strategic partnerships, clinical trial collaborations, and orphan drug designations are common competitive strategies.

Conclusion
The Overt Hepatic Encephalopathy Market is set for robust growth over the next decade, fueled by the rising burden of liver disease, adoption of rifaximin-lactulose therapy, and pipeline innovation in microbiome and biologic treatments. From USD 1.4 billion in 2024, the market is projected to nearly double to USD 2.9 billion by 2034, growing at a CAGR of 7.5%.

Key opportunities include:
• Expanding access to rifaximin and advanced therapies in emerging economies.
• Fast-tracking clinical development of microbiome-based therapies.
• Leveraging digital health and AI for patient monitoring.
• Improving early screening and intervention for cirrhosis patients.

This report is also available in the following languages : Japanese (顕性肝性脳症市場), Korean (명백한 간성 뇌병증 시장), Chinese (显性肝性脑病市场), French (Marché de l'encéphalopathie hépatique manifeste), German (Markt für offene hepatische Enzephalopathie), and Italian (Mercato dell'encefalopatia epatica manifesta), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71156

Our More Reports:

Contusion Market
https://exactitudeconsultancy.com/reports/71406/contusion-market

Drug Eruptions Market
https://exactitudeconsultancy.com/reports/71408/drug-eruptions-market

Eczema Market
https://exactitudeconsultancy.com/reports/71410/eczema-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.

https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Overt Hepatic Encephalopathy (OHE) Market New Product Development & Latest Trends here

News-ID: 4160061 • Views:

More Releases from Exactitude Consultancy

Tropical Spastic Paraparesis Market to Reach USD 1.3 Billion by 2034
Tropical Spastic Paraparesis Market to Reach USD 1.3 Billion by 2034
Tropical spastic paraparesis (TSP), also known as HTLV-1-associated myelopathy (HAM/TSP), is a chronic, progressive neurological disorder caused by infection with the human T-cell lymphotropic virus type 1 (HTLV-1). The condition is most prevalent in parts of Africa, the Caribbean, South America, Japan, and the Middle East, with patients experiencing progressive weakness, stiffness, sensory disturbances, and bladder dysfunction due to spinal cord inflammation. Download Full PDF Sample Copy of Market Report @
Bipolar Disorder (Manic Depression) Market to Reach USD 14.8 Billion by 2034
Bipolar Disorder (Manic Depression) Market to Reach USD 14.8 Billion by 2034
Bipolar disorder, also known as manic depression, is a chronic psychiatric condition characterized by extreme mood swings, ranging from manic or hypomanic episodes to depressive phases. It affects an estimated 40-45 million people worldwide, significantly impacting quality of life, social functioning, and productivity. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72083 Traditionally managed with mood stabilizers (lithium, valproate), antipsychotics, and antidepressants, treatment has evolved with the introduction of atypical antipsychotics,
Postoperative Pain Market is expected to reach USD 58.9 billion by 2034
Postoperative Pain Market is expected to reach USD 58.9 billion by 2034
Postoperative pain is one of the most common and challenging complications following surgery. Effective pain control is crucial for patient recovery, reduced hospital stays, and prevention of chronic pain syndromes. Globally, more than 300 million surgeries are performed annually, and the increasing prevalence of chronic diseases, trauma, orthopedic conditions, and cancer has driven surgical demand. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72085 Traditionally, pain has been managed with opioids,
Dravet Syndrome (DS) market is expected to reach USD 1.9 billion by 2034
Dravet Syndrome (DS) market is expected to reach USD 1.9 billion by 2034
Dravet syndrome (DS) is a rare, severe, and lifelong form of epilepsy that typically begins in infancy. Characterized by prolonged seizures, developmental delays, motor impairments, and increased mortality risk, DS is caused primarily by mutations in the SCN1A gene. With an estimated incidence of 1 in 15,000-20,000 live births, DS is a rare but devastating condition that significantly impacts patients and families. Download Full PDF Sample Copy of Market Report @

All 5 Releases


More Releases for OHE

Overt Hepatic Encephalopathy (OHE) Market Emerging Trends and Growth Prospects 2 …
Introduction Overt Hepatic Encephalopathy (OHE) is a severe neuropsychiatric complication of chronic liver disease, particularly cirrhosis, characterized by altered mental status, confusion, impaired coordination, and, in severe cases, coma. It occurs due to the accumulation of toxins such as ammonia in the bloodstream, which the impaired liver cannot adequately clear. OHE poses a significant healthcare challenge as it leads to frequent hospitalizations, reduced quality of life, and increased mortality. With the global
Global Silica Gel Desiccant Market Growing Popularity & Emerging Trends - Claria …
The global Silica Gel Desiccant Market size reached 2,742 USD Million in 2024. Looking forward, MarketsGlob expects the market to reach 3,930.86 USD Million by 2031, exhibiting a growth rate (CAGR) of 5.28% during 2025-2031. A recent report published by MarketsGlob offers an in-depth analysis of the Global Silica Gel Desiccant Market, projecting trends and market size through 2031. This comprehensive study serves as a valuable reference for industry professionals, including
Air and Gas Drying Desiccants Market 2023 Future Trends, Dynamic Growth & Foreca …
Air and Gas Drying Desiccants Market 2023 Opportunities and Growth - According to QYResearch's new survey on Air and Gas Drying Desiccants Market Research Report 2023 to 2029, a cornerstone of countless sectors, is primed for a new era of innovation and growth. This revolutionary Market Research Report dives deep into the essence of the Air and Gas Drying Desiccants sector, unraveling its significance and its transformative role in various
Silicone Desiccant Market 2023: Eminent Players - Multisorb, Grace, Sorbead, OhE …
Silicone Desiccant Market Report Overview: Silicone Desiccant report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Silicone Desiccant market is projected to reach US$ 941.8 million in 2029, increasing from US$ 805 million in 2022, with the CAGR of 2.3% during the period of 2023 to 2029. Demand from Electronics Industry and Pharmaceutical Industry are the major drivers for the industry. This comprehensive
New Edition 2020: Desiccant Market Analysis by Top Players- OhE Chemicals, Miner …
Global Desiccant Market: Snapshot Global Desiccant Industry 2020 Market Research Report provide the details about Industry Overview and analysis about Manufacturing Cost Structure, Revenue, Gross Margin, Consumption Value and Sale Price, Major Manufacturers, Distributors, Industry Chain Structure, New Project SWOT Analysis with Development Trends and Forecasts 2025 Get Sample Copy of this Report @https://www.orianresearch.com/request-sample/1521016 Further, in the research report, the following points are included along with an in-depth study of each point: * Production
Desiccant Market Size Detail Analysis focusing on Key Players like BASF , Claria …
Market Study Report delivers significant information and realistic data of the Desiccant market . The report presents a deep study of the market growth factors and drivers. In-depth research of the Desiccant Market limitations and the opportunities enable the user to make the future projection. Scope of the Report: The worldwide market for Desiccant is expected to grow at a CAGR of roughly over the next five years, will reach million US$